vVardis, a Switzerland-based dental medtech company, has received a minority investment from Apollo Funds to accelerate growth and expand its commercial reach. The funding will support the rollout of the company's Curodont product suite, a non-invasive peptide-based formulation designed to treat tooth decay.

What is Curodont technology

Curodont is the first and only commercially available non-invasive peptide-containing formulation clinically proven to treat tooth decay. The product represents an alternative approach to conventional caries management, using peptide technology rather than traditional restorative methods.

Growth and market expansion plans

The investment will fund continued product rollout and commercial expansion of the Curodont suite. The backing from Apollo Funds signals investor confidence in the company's technology and market potential as it moves into its next growth phase.